Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New heart pump may reduce death and stroke in risky surgeries

NCT ID NCT05756751

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the Impella 5.5 heart pump in 123 high-risk patients with weak hearts (ejection fraction 25% or less) who need complex cardiac surgery. The pump supports the heart during and after surgery to prevent failure, stroke, and other complications. The goal is to confirm the device's safety and effectiveness in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

123 people

The number who actually took part.

Started

Apr 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Hemodynamically stable patients undergoing one (1) of the following cardiac surgery procedures on CPB including aortic cross-clamping and cardioplegic arrest * Isolated CABG * Isolated mitral valve repair or replacement (MVR) * Isolated aortic valve repair or replacement (AVR) * At lest two of the following: CABG, MVR, AVR, or tricuspid valve repair or replacement (TVR) 2. LVEF within 30 days before surgery of either: * ≤25% measured by echocardiogram or * LVEF ≤35% as above for patients with significant mitral regurgitation (MR 3+ or 4+; see definition) and planned corrective mitral valve surgery (including MV replacement or repair) 3. Age 18 years or older 4. Subject has signed informed consent form and is willing and able to attend all follow-up visits and to perform all tests. 5. Patient is eligible to receive the Impella 5.5 as per the current IFU. Exclusion Criteria: 1. Salvage operation (cardiac arrest within 24 hours prior to index surgery) 2. Unresponsive state within 24 hours of the time of surgery 3. Any inotrope within 72 hours of surgery 4. Any mechanical MCS device (such as IABP, ECMO, Impella®, CentriMag™ or TandemHeart®) in place prior to informed consent 5. RV dysfunction requiring mechanical or inotropic support preoperatively and/or likely to be needed postoperatively 6. Index procedures requiring total circulatory arrest (TCA), such as aortic arch replacement, planned durable LVAD, durable RVAD, planned right-sided temporary mechanical support of any kind, total artificial heart (TAH), cardiac transplantation, pericardiectomy, pulmonary thromboendarterectomy and septal myectomy 7. Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade or other conditions in which cardiac output is dependent on venous return 8. Ventricular septal defect (VSD) 9. Stroke within 30 days of the index cardiac surgical procedure 10. Prior mantle field chest irradiation 11. Prior solid organ or hematologic transplantation (heart, kidney, liver, lung, pancreas, bone marrow) or durable LVAD 12. History of chronic dialysis 13. Pre-existing liver dysfunction defined as Child-Pugh Class B or C 14. Pre-existing pulmonary disease requiring home oxygen, or "severe pulmonary disease" determined by enrolling investigator 15. Systemic active infection or evidence of systemic bacterial, fungal or viral infection within 72 hours before surgery (blood culture positive with leukocytosis) 16. Confirmed COVID-19 infection within two (2) weeks prior to operation 17. Pregnant or planning pregnancy within next 12 months. NOTE: Female patients of childbearing potential need to have a negative pregnancy test performed within 14 days prior to intervention. 18. Participation in the active treatment or follow-up phase of another interventional clinical trial of an investigational drug or device which has not reached its primary endpoint 19. Known contraindication to heparin; History of bleeding diathesis or known coagulopathy or will refuse blood transfusions 20. Inability to perform aortic cross-clamp, such as due to porcelain aorta 21. Any contraindication or condition that would prevent the ability to place Impella 5.5® (per current IFU), including LV thrombus and/or presence of a mechanical aortic valve 22. Any organ condition, concomitant disease (e.g., psychiatric illness, current severe alcoholism or current drug abuse, cancer, hepatic or kidney disease), with life expectancy of ≤2 years or other abnormality that itself or the treatment of which, could interfere with the conduct of the trial or that, in the opinion of the investigator would pose an unacceptable risk to the subject in the trial. 23. Subject has other medical, social or psychological problems that, in the opinion of the investigator, compromises the subject's ability to give written informed consent and/or to comply with trial procedures, including patients under guardianship 24. Any subject considered to be part of a vulnerable population (as per ISO 14155)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Left ventricular dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

left ventricular failure Ventricular Dysfunction, Left

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Deutsches Herzzentrum der Charité

    Berlin, 13353, Germany

  • IKEM Prague

    Prague, 14021, Czechia

  • Krankenhaus der Barmherzigen Brüder Trier

    Trier, 54292, Germany

  • Medizinische Hochschule Hannover

    Hanover, 30625, Germany

  • RWTH Uniklinik Aachen - Klinik für Herzchirurgie

    Aachen, North Rhine-Westphalia, 52074, Germany

  • UKSH Campus Kiel - Klinik für Herz- und Gefäßchirurgie

    Kiel, Schleswig-Holstein, 24105, Germany

  • Universitäres Herz- und Gefäßzentrum Hamburg - Klinik und Poliklinik für Herz- und Gefäßchirurgie

    Hamburg, 20246, Germany

  • Universitätsklinikum Düsseldorf, Klinik für Herzchirurgie

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • Universitätsklinikum Giessen

    Giessen, 35392, Germany

  • Universitätsklinikum Heidelberg - Klinik für Herzchirurgie

    Heidelberg, Baden-Wurttemberg, 69120, Germany

  • Universitätsmedizin Essen, Westdeutsches Herzzentrum, Klinik für Thorax- und Kardiovaskuläre Medizin

    Essen, North Rhine-Westphalia, 45147, Germany

  • Universitätsmedizin Halle/Saale - Klinik für Herzchirurgie

    Halle, SA, 06120, Germany

  • Universitätsmedizin Mainz, Klinik und Poliklinik für Herz- und Gefäßchirurgie

    Mainz, RLP, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.